CRISPR/Cas9-mediated abrogation of CD95L/CD95 signaling-induced glioma cell growth and immunosuppression increases survival in murine glioma models [PDF]
Journal of Neuro-Oncology, 2022 PURPOSE: Glioblastoma is the most common brain tumor in adults and is virtually incurable. Therefore, new therapeutic strategies are urgently needed. Over the last decade, multiple growth-promoting functions have been attributed to CD95, a prototypic ...
Michael Weller
exaly +4 more sources
Therapeutic approaches targeting CD95L/CD95 signaling in cancer and autoimmune diseases
Cell Death and Disease, 2022 Cell death plays a pivotal role in the maintenance of tissue homeostasis. Key players in the controlled induction of cell death are the Death Receptors (DR).
Vesna Risso +2 more
doaj +2 more sources
A Novel Tetravalent CD95/Fas Fusion Protein With Superior CD95L/FasL Antagonism [PDF]
Proteins: Structure, Function and BioinformaticsInhibition of CD95/Fas activation is currently under clinical investigation as a therapy for glioblastoma multiforme and preclinical studies suggest that disruption of the CD95–CD95L interaction could also be a strategy to treat inflammatory and ...
Harald Wajant +2 more
exaly +3 more sources
Cleaved CD95L perturbs in vitro macrophages responses to Toxoplasma gondii [PDF]
Microbes and Infection, 2022 Toxoplasma gondii infects approximately 1-2 billion people, and manipulation of the macrophage response is critical to host and parasite survival. A cleaved (cl)-CD95L form can promote cellular migration and we have previously shown that cl-CD95L aggravates inflammation and pathology in systemic lupus erythematosus (SLE). Findings have shown that CD95L
Tiffney, Ellen A +3 more
openaire +5 more sources
The naturally processed CD95L elicits a c-yes/calcium/PI3K-driven cell migration pathway. [PDF]
PLoS Biology, 2011 Patients affected by chronic inflammatory disorders display high amounts of soluble CD95L. This homotrimeric ligand arises from the cleavage by metalloproteases of its membrane-bound counterpart, a strong apoptotic inducer.
Sébastien Tauzin +13 more
doaj +3 more sources
Cytoplasmic Overexpression of CD95L in Esophageal Adenocarcinoma Cells Overcomes Resistance to CD95-Mediated Apoptosis [PDF]
Neoplasia: An International Journal for Oncology Research, 2011 Introduction: The CD95/CD95L pathway plays a critical role in tissue homeostasis and immune system regulation; however, the function of this pathway in malignancy remains poorly understood.
Gregory A. Watson +5 more
doaj +2 more sources
Inhibition of NF‐κB induces a switch from CD95L‐dependent to CD95L‐independent and JNK‐mediated apoptosis in T cells [PDF]
FEBS Letters, 2010 NF‐κB is a crucial transcription factor regulating apoptosis sensitivity and resistance. It has been shown that inhibition of NF‐κB in T lymphocytes leads to sensitization towards apoptosis. The underlying molecular mechanism is not entirely understood.
Kießling, Michael K. +5 more
openaire +4 more sources
TRAF2 inhibits TRAIL- and CD95L-induced apoptosis and necroptosis [PDF]
Cell Death & Disease, 2014 AbstractThe relevance of the adaptor protein TNF receptor-associated factor 2 (TRAF2) for signal transduction of the death receptor tumour necrosis factor receptor1 (TNFR1) is well-established. The role of TRAF2 for signalling by CD95 and the TNF-related apoptosis inducing ligand (TRAIL) DRs, however, is only poorly understood.
Karl, I. +7 more
openaire +5 more sources
Pre-existing CD95-based Temra immunity in patients with recurrent/metastatic nasopharyngeal carcinoma predicts response and hyperprogression to dual PD-L1 and TGFβ inhibition. [PDF]
Clin Transl Med• Lower baseline CD95⁺ Temra levels were associated with treatment response and longer survival. • Higher CD57⁺ Temra frequencies predicted improved overall survival, independent of response. • Post‐treatment shifts in CD95/CD57 expression correlated with survival outcomes.
Kam NW +8 more
europepmc +2 more sources
Activation of CD95L fusion protein prodrugs by tumor-associated proteases [PDF]
Cell Death and Differentiation, 2006 To achieve tumor cell-restricted activation of CD95, we developed a CD95L fusion protein format, in which CD95L activity is only unmasked upon antibody-mediated binding to tumor cells and subsequent processing by tumor-associated proteases, such as matrix metalloproteases (MMPs) and urokinase plasminogen activator (uPA).
Harald Wajant
exaly +4 more sources